Table 3.

Risk of renal relapse after adjustment for duration of hematuria and proteinuria in ANCA-associated vasculitis

VariablesHR (95% CI)P Value
Cumulative duration of hematuria (per mo)1.08 (1.03 to 1.12)<0.01
Cumulative duration of proteinuria (per mo)1.04 (0.99 to 1.08)0.10
ANCA (anti-PR3 versus anti-MPO)0.77 (0.30 to 1.92)0.57
Baseline pulmonary involvement2.84 (0.34 to 23.98)0.34
Baseline creatinine per 1 mg/dl0.94 (0.48 to 1.83)0.85
Study (the RAVE Trial versus the WGET)0.30 (0.06 to 1.64)0.17
  • Cumulative durations of hematuria and proteinuria were analyzed as time-varying covariates. Hematuria by proteinuria interaction was not significant (P for interaction =0.11). sHR, subdistribution hazard ratio; 95% CI, 95% confidence interval; PR3, proteinase 3; MPO, myeloperoxidase; RAVE, Rituximab in ANCA-Associated Vasculitis; WGET, Wegener’s Granulomatosis Etanercept Trial.